Table 1.

Baseline characteristics of subject subsets using 150 day, and very early versus very late cutoff times. Data are mean (SD) unless otherwise indicated.

Cutpoint
150 Days (5 months)Very EarlyVery Late
CharacteristicEarly, < 150 DaysLate, ≥ 150 DaysEarly, < 90 Days (< 3 mo)Late, ≥ 300 Days (≥ 10 mo)
No. (n = 233)1101235149
Female, %77767669
Age, yrs51.5 (12.4)49.4 (13.1)53.3 (11.1)48.1 (14.11)*
Time to first DMARD, mo3.1 (1.3)9.1 (3.0)1.9 (0.7)12.2 (1.9)
Tender joint count, 0–6923.5 (14.3)22.7 (12.0)19.6 (12.5)23.1 (13.9)
Swollen joint count, 0–6620.0 (11.4)19.2 (10.1)23.4 (15.5)20.9 (11.3)
Physician global assessment, 0–100 scale52.5 (21.03)47.7 (20.50)52.3 (21.16)48.3 (20.5)
Patient global assessment, 0–100 scale44.3 (28.3)43.3 (27.9)46.3 (27.3)45.7 (26.9)
Disease activity score (DAS-44-ESR)4.73 (1.18)4.76 (1.16)4.60 (1.33)4.92 (1.19)
Health Assessment Questionnaire, 0–31.35 (0.72)1.09 (0.68)**1.41 (0.71)1.03 (0.56)**
Rheumatoid factor titer, IU/ml360.44 (405.9)389.3 (624.0)385.3 (428.5)399.9 (724.2)
Anti-CCP (no. positive/total), % positive43/48 (90)60/69 (87)19/21 (90)25/28 (89)
C-reactive protein, mg/dl2.95 (3.57)2.90 (4.01)2.74 (3.36)2.9 (3.79)
Erythrocyte sedimentation rate, mm/h41.4 (23.1)41.0 (26.3)41.3 (24.5)48.0 (30.4)
Erosion score1.49 (2.18)2.60 (4.74)1.55 (2.45)3.59 (4.29)**
Joint space narrowing score3.78 (4.51)4.07 (6.80)4.50 (4.73)4.94 (8.84)
Total Sharp Score5.27 (5.69)6.67 (9.97)6.06 (6.43)8.53 (12.32)
  • * Significantly different at p < 0.05, earlier versus later institution of DMARD, using the Wilcoxon rank-sum test for continuous variables and chi-square test for categorical variables.

  • ** Significantly different at p < 0.01, earlier versus later institution of DMARD, using the Wilcoxon rank-sum test for continuous variables and chi-square test for categorical variables.